Evommune (EVMN)
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflam...
- Open
- 13.080
- High
- 13.130
- Low
- 12.610
- Prev. Close
- 13.230
- Volume
- 571.94K
- Turnover
- 7.27M
- Avg Price
- 12.720
- Bid/Ask Ratio
- 98.02%
- Amplitude
- 3.93%
- 52wk High
- 33.200
- Volume Ratio
- 0.61
- Turnover Ratio
- 2.88%
Evommune Analyst Rating
View moreForecast & Rating
Aug 26, 2026Price forecast
$27.63118.21%
Forecast & RatingBuy
11analysts
- Strong buy45.45%
- Buy36.36%
- Hold18.18%
- Sell0.00%
- Strong sell0.00%
News
- benzinga_article · Aug 26 at 08:15 AM
This Atlassian Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
- Tip Ranks · Aug 10 at 07:45 AM
Evercore ISI Keeps Their Buy Rating on Evommune, Inc. (EVMN)
- Market Beat · Aug 7 at 02:30 PM
Evommune (NYSE:EVMN) Price Target Cut to $29.00 by Analysts at Royal Bank Of Canada
- PUBT · Aug 6 at 05:11 PM
Evommune posts corporate presentation outlining Phase 2 inflammation-drug pipeline focusing on EVO756, EVO301
- PUBT · Aug 6 at 03:17 PM
Evommune Q2 FY26 net loss widens to $32.25 million
- WorldPharmaceuticals · Jul 31 at 05:13 AM
Evommune begins Phase IIb trial of EVO756 for migraine
